BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#316 of 347

Jason McCarthy

Maxim Group · Equity Research Analyst
EstablishedRating since 2018No new ratings since May 2025

Analyst rating accuracy & track record

Jason McCarthy is an equity research analyst at Maxim Group. Bullish Whales has scored 59 of their stock calls across 42 companies. Their picks beat their sector 30% of the time over the next 12 months, and their price targets were reached 21% of the time within a year.

Win % vs sector
30%
PT Hit % (12mo)
21%
Avg sector-excess
−25.9%
Scored calls
59
Tickers
42
Tier
Established

Track record

Bullish Whales has scored 59 of Jason McCarthy's stock calls across 42 companies, dating back to 2018. Their rated stocks beat their own sector 30% of the time over the next 12 months. On a typical call, a McCarthy pick returned −25.9% more than its sector over the following year.

Of the scored calls, 59 were bullish (Buy). Most of their coverage sits in Unknown. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
BNGOBionano Genomics Inc
Buy$8.00May 2025−79.6%Miss
MTVAMetaVia Inc.
Buy$3.00May 2025−86.6%Hit
CEROCERo Therapeutics Holdings, Inc. Common Stock
Buy$3.00May 2025−111.1%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$20.00May 2025−124.9%Miss
MBRXMoleculin Biotech Inc
Buy$4.00Mar 2025−93.5%Miss
ANIXAnixa Biosciences Inc
Buy$10.00Mar 2025−18.6%Miss
ONCYOncolytics Biotech Inc
Buy$3.00Mar 2025+59.8%Miss
INMBINmune Bio Inc
Buy$30.00Feb 2025−95.1%Miss
KZIAKazia Therapeutics Ltd ADR
Buy$3.00Feb 2025−17.7%Hit
ATHEAlterity Therapeutics Ltd
Buy$12.00Jan 2025−41.2%Miss
RVPHReviva Pharmaceuticals Holdings Inc.
Buy$7.00Jan 2025−96.2%Miss
MDCXMedicus Pharma Ltd. Common Stock
Buy$10.00Dec 2024−42.8%Miss
ATHEAlterity Therapeutics Ltd
Buy$8.00Dec 2024+25.9%Miss
BLTEBelite Bio Inc ADR
Buy$110.00Nov 2024+32.5%Hit
INDPIndaptus Therapeutics Inc
Buy$5.00Nov 2024−98.2%Miss
TOVXTheriva Biologics Inc.
Buy$6.00Nov 2024−93.9%Miss
MBRXMoleculin Biotech Inc
Buy$8.00Nov 2024−86.5%Miss
QNCXQuince Therapeutics, Inc.
Buy$6.00Nov 2024−7.3%Miss
CMPSCompass Pathways Plc
Buy$12.00Nov 2024+27.0%Miss
ANVSAnnovis Bio Inc
Buy$25.00Oct 2024−78.0%Miss
CAPRCapricor Therapeutics Inc
Buy$25.00Sep 2024−23.9%Miss
MESOMesoblast Ltd
Buy$12.00Sep 2024+142.0%Hit
ZVRAZevra Therapeutics Inc.
Buy$25.00Sep 2024+27.6%Miss
CAPRCapricor Therapeutics Inc
Buy$12.00Sep 2024+28.9%Hit
CNSPCNS Pharmaceuticals Inc
Buy$0.50Sep 2024−82.6%Miss
RZLTRezolute Inc
Buy$10.00Aug 2024+42.7%Miss
ATNMActinium Pharmaceuticals Inc
Buy$5.00Aug 2024−47.3%Miss
BCLIBrainstorm Cell Therapeutics Inc
Buy$2.00Jul 2024−73.7%Miss
CNTXContext Therapeutics Inc
Buy$10.00May 2024−52.1%Miss
LIPOLipella Pharmaceuticals Inc. Common Stock
Buy$2.00Apr 2024−60.9%Miss
ATAIATAI Life Sciences BV
Buy$6.00Apr 2024−50.1%Miss
MBRXMoleculin Biotech Inc
Buy$20.00Mar 2024−80.3%Miss
ATNMActinium Pharmaceuticals Inc
Buy$30.00Mar 2024−95.9%Miss
ATXIAvenue Therapeutics Inc
Buy$0.75Dec 2023−115.2%Hit
NEUPNeuphoria Therapeutics Inc
Buy$10.00Sep 2023−97.0%Miss
GNLXGenelux Corporation Common Stock
Buy$40.00Sep 2023−106.5%Miss
CNTXContext Therapeutics Inc
Buy$4.00Sep 2023+83.7%Miss
VTGNVistaGen Therapeutics Inc
Buy$30.00Sep 2023−71.1%Miss
VTGNVistaGen Therapeutics Inc
Buy$30.00Aug 2023−67.9%Miss
GLMDGalmed Pharmaceuticals Ltd
Buy$4.00Jul 2023−84.7%Miss
NEUPNeuphoria Therapeutics Inc
Buy$7.00Jun 2023−80.9%Miss
IMMPImmutep Ltd ADR
Buy$10.00May 2023+7.6%Miss
BCLIBrainstorm Cell Therapeutics Inc
Buy$10.00Mar 2023−89.0%Miss
APREAprea Therapeutics Inc
Buy$16.00Mar 2023+13.9%Miss
ACHVAchieve Life Sciences Inc
Buy$8.00Nov 2022+128.2%Hit
ONCYOncolytics Biotech Inc
Buy$3.00Oct 2022+52.9%Hit
GOVXGeoVax Labs Inc
Buy$6.00May 2022−71.9%Miss
ACXPAcurx Pharmaceuticals LLC
Buy$12.00Nov 2021−43.1%Miss
PTIXProtagenic Therapeutics
Buy$4.00Oct 2021−72.2%Miss
MNOVMediciNova Inc
Buy$15.00Mar 2021−82.9%Miss
Go to

Jason McCarthy: analyst track record FAQ

Is Jason McCarthy a good stock analyst?

Yes, by track record. Jason McCarthy ranks number 316 of 347 of the analysts Bullish Whales scores, with a BW Score of 0 out of 100. Past results do not guarantee future ones.

What is Jason McCarthy's win rate?

Jason McCarthy's win rate is 30%. Across 59 scored calls, their rated stocks beat their sector 30% of the time over the next 12 months. On a typical call they returned −25.9% more than the sector.

What stocks and sectors does Jason McCarthy cover?

Jason McCarthy covers 42 companies, with the most coverage in Unknown. See the ratings table above for every scored call and its outcome.

Are Jason McCarthy's price targets accurate?

Jason McCarthy's price targets are reached within 12 months 21% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Jason McCarthy's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Jason McCarthy rank among Wall Street analysts?

Jason McCarthy ranks number 316 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30